Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H31N3O4 |
| Molecular Weight | 449.542 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NCCCOC1=CC=C(C=C1)C(=O)N2CCC(CC2)N3C(=O)CCC4=C3C=CC=C4
InChI
InChIKey=KSNUCNRMDYJBKT-UHFFFAOYSA-N
InChI=1S/C26H31N3O4/c1-19(30)27-15-4-18-33-23-10-7-21(8-11-23)26(32)28-16-13-22(14-17-28)29-24-6-3-2-5-20(24)9-12-25(29)31/h2-3,5-8,10-11,22H,4,9,12-18H2,1H3,(H,27,30)
| Molecular Formula | C26H31N3O4 |
| Molecular Weight | 449.542 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800000284 | https://www.ncbi.nlm.nih.gov/pubmed/8228734
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800000284 | https://www.ncbi.nlm.nih.gov/pubmed/8228734
OPC-21268, a non-peptide vasopressin V1 receptor antagonist, inhibited oxytocin- and vasopressin-induced contractions of myometrial strips from rats and from full-term pregnant women. OPC-21268, because of its non-peptide structure, is orally active and has been shown to lower blood pressure in a patient with congestive heart failure and in spontaneously hypertensive rats. It also attenuates vasopressin induced bradycardia in rabbits and pressor responses in rats. It has been demonstrated that OPC-21268 exerts its inhibitory action through binding to the vasopressin V1 receptors in rat liver and kidney. Finally, OPC-21268 was reported to be safe and non-toxic in healthy humans. Merck scientists showed that OPC-21268 had significant affinity for the rOTR and the hOTR. OPC-21268 has been in phase II clinical trials by Otsuka for the treatment of heart failure and hypertension. However, this research has been discontinued.
Originator
Approval Year
Sample Use Guides
Single oral administration of OPC-21268 (100 mg) in hypertensive patients on diets
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: In human internal mammary arteries, the non-peptide V1 receptor antagonist, OPC-21268, failed to antagonize vasopressin-induced contraction at low concentrations and potentiated the contraction at higher concentrations (300 nmol/l, P < 0.05). In rat mesenteric resistance arteries, OPC-21268 (10 nmol/l) antagonized vasopressin-induced contraction
In endothelium-intact human coronary artery segments, OPC-21268 (3uM) induced a rightward shift of the vasopressin concentration-response curve.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:04:48 GMT 2023
by
admin
on
Sat Dec 16 11:04:48 GMT 2023
|
| Record UNII |
33U7944QCQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
114904
Created by
admin on Sat Dec 16 11:04:48 GMT 2023 , Edited by admin on Sat Dec 16 11:04:48 GMT 2023
|
PRIMARY | |||
|
131631-89-5
Created by
admin on Sat Dec 16 11:04:48 GMT 2023 , Edited by admin on Sat Dec 16 11:04:48 GMT 2023
|
PRIMARY | |||
|
33U7944QCQ
Created by
admin on Sat Dec 16 11:04:48 GMT 2023 , Edited by admin on Sat Dec 16 11:04:48 GMT 2023
|
PRIMARY | |||
|
DTXSID70927295
Created by
admin on Sat Dec 16 11:04:48 GMT 2023 , Edited by admin on Sat Dec 16 11:04:48 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
NON-INHIBITOR->OFF-TARGET |
Inhibits Rat receptor but not human
Ki
|
